Bevacizumab-treated pregnant rats may constitute an experimental model for studying preeclampsia

Purpose: To develop a rat model of preeclampsia by administering bevacizumab, an angiogenesis inhibitor. Materials and methods: Sixteen pregnant rats were randomly allocated to intraperitoneal injection of 10 mg/kg bevacizumab or 0.1 cc intraperitoneal serum physiologic on the 4th and 8th days of gestation. Blood pressure, body weight, and proteinuria were measured on both day 0 (D0) and day 20 (D20). Blood samples were collected on D20 for analysis, including for determining vascular endothelial growth factor (VEGF) and soluble Fms-like tyrosine kinase 1 (sFlt-1) levels. On the same day, the mice were euthanized, the placentas and pups were weighted, and the angiogenesis markers and microvessel density were evaluated using immunohistochemical methods. Results: Lower serum VEGF (p=0.038) and higher SFlt-1 (p=0.015) levels were observed in bevacizumabtreated pregnant rats. Bevacizumab-treated pregnant rats had significantly higher systolic (p=0.050) and diastolic (p = 0.046) blood pressures compared to the controls. Additionally, the bevacizumab group showed a significant increase in proteinuria on D20 compared to that on D0 (p=0.026). Although higher serum AST, ALT, BUN, and creatinine levels and renal glomerular endotheliosis scores as well as lower placental VEGF and microvessel density were noted in bevacizumab-treated rats, these differences were not statistically significant (p > 0.05 for each). Conclusion: The promising results of this trial show that bevacizumab treatment in pregnant rats might provide a model to study human preeclampsia.

Gebe sıçanlara bevacizumab uygulayarak preeklampsi çalışmalarında kullanılabilecek deneysel hayvan modeli oluşturulabilir

Amaç: Bir anjiogenez inhibitörü olan bevacizumab uygulayarak sıçanlarda preeklampsi modeli oluşturmak. Gereç ve Yöntem: Toplam 16 gebe sıçana intraperitoneal 10 mg/kg bevacizumab ya da 0.1 cc serum fizyolojik 4 ve 8. günlerde uygulandı. Sıçanların kan basınçları, ağırlıkları ve proteinüri miktarları 0 ve 20. günlerde değerlendirildi. 20. günde sıçanlardan kan örnekleri alınarak vasküler endotelyal büyüme faktörü (VEGF) ve çözülebilir Fms benzeri protein kinaz (SFlt-1) seviyeleri ölçüldü. Aynı gün ötenazi uygulanılarak plasenta ve yavruların ağırlıkları değerlendirildi. Immünohistokimyasal olarak anjiogenez belirteçleri ve mikro damar yoğunluğu incelendi. Bulgular: Bevacizumab uygulanan grupta daha düşük VEGF (p=0.038) ve daha yüksek SFlt-1 (p=0.015) seviyeleri saptandı. Benzer şekilde bevacizumab uygulanan sıçanların sistolik (p=0.050) ve diastolik (p=0.046) kan basınçları daha yüksek bulundu. Bevacizumab uygulanan sıçanlarda 20. günde proteinüri miktarları 0. güne göre belirgin olarak daha yüksekti (p=0.026). Her ne kadar daha yüksek AST, ALT, BUN, kreatinin, böbrek glomerüler endotelyosis skorları ile daha düşük plasental VEGF ve mikro damar yoğunluğu gözlenmiş olsa da, istatistiksel olarak anlamlı fark saptanmadı (p>0.05). Sonuç:Çalışmamızda gebe sıçanlara bevacizumab uygulayarak preeklampsi modeli oluşturulabileceğine dair olumlu sonuçlar elde edilmiştir.

___

ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol 2002;99:159-167.

Barton JR, Sibai BM. Prediction and prevention of recurrent preeclampsia. Obstet Gynecol 2008;112:359- 372.

Makrides M, Duley L, Olsen SF. Marine oil, and other prostaglandin precursor, supplementation for pregnancy uncomplicated by pre-eclampsia or intrauterine growth restriction. Cochrane Database Syst Rev 2006;3:CD003402.

Roberts JM, Myatt L, Spong CY, et al. Vitamins C and E to prevent complications of pregnancy-associated hypertension. N Engl J Med 2010;362:1282-1291.

Xu H, Perez-Cuevas R, Xiong X, et al. An international trial of antioxidants in the prevention of preeclampsia (INTAPP). Am J Obstet Gynecol 2010;202:1-10.

Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672-683.

Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006;355:992-1005.

Tischer E, Mitchell R, Hartman T, et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991;266:11947-11954.

Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-676.

Ku DD, Zaleski JK, Liu S, Brock TA. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Am J Physiol 1993;265:586-592.

Zachary I. Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am J Physiol Cell Physiol 2001;280:1375-1386.

Sugimoto H, Hamano Y, Charytan D, et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 2003;278:12605-12608.

Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007;49:186-193.

Claesson-Welsh L. Vascular Endothelial Growth Factors. Springer 1999:123.

Waltenberger J, Mayr U, Frank H, Hombach V. Suramin is a potent inhibitor of vascular endothelial growth factor. A contribution to the molecular basis of its antiangiogenic action. J Mol Cell Cardiol 1996;28:1523-1529.

Nash P, Wentzel P, Lindeberg S, et al. Placental dysfunction in Suramin-treated rats--a new model for pre-eclampsia. Placenta 2005;26:410-418.

Ahmed A. Heparin-binding angiogenic growth factors in pregnancy. Trophoblast Res 1997;18:215-58.

Buñag RD, Butterfield J. Tail-cuff blood pressure measurement without external preheating in awake rats. Hypertension 1982;4:898-903.

Donnez J, Smoes P, Gillerot S, Casanas-Roux F, Nisolle M. Vascular endothelial growth factor (VEGF) in endometriosis. Hum Reprod 1998;13:1686-1690.

Li Z, Zhang Y, Ying Ma J, et al. Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension 2007;50:686-692.

Podjarny E, Baylis C, Losonczy G. Animal models of preeclampsia. Semin Perinatol 1999;23:2-13.

Bdolah Y, Karumanchi SA, Sachs BP. Recent advances in understanding of preeclampsia. Croat Med J 2005;46:728-736.

Yang R, Ogasawara AK, Zioncheck TF, et al. Exaggerated hypotensive effect of vascular endothelial growth factor in spontaneously hypertensive rats. Hypertension 2002;39:815-820.

Zhou Y, McMaster M, Woo K, et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol 2002;160:1405-1423.

Wang A, Rana S, Karumanchi SA. Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology (Bethesda) 2009;24:147-158.

Carlström M, Wentzel P, Skøtt O, Persson AE, Eriksson UJ. Angiogenesis inhibition causes hypertension and placental dysfunction in a rat model of preeclampsia. J Hypertens 2009;27:829-837.

Turgut NH, Temiz TK, Bagcivan I, Turgut B, Gulturk S, Karadas B. The effect of sildenafil on the altered thoracic aorta smooth muscle responses in rat preeclampsia model. Eur J Pharmacol 2008;589:180-187.

Maeda K, Ohkura S, Tsukamura H. Physiology of reproduction. In: Krinke GJ, editor. The Laboratory Rat, New York: Academic Press, 2000;145-176.

Ignjatovic D, Aasland K, Pettersen M, et al. Intraabdominal administration of bevacizumab diminishes intra-peritoneal adhesions. Am J Surg 2010;200:270- 275.

Passot G, Dupré A, Rivoire M, Mohamed F, Bakrin N, Glehen O. Intraperitoneal bevacizumab combined with cytoreductive surgery: a pre-clinical study of tolerance and pharmacokinetics in an animal model. Clin Transl Oncol 2012;14:931-936.

Moraloglu O, Işik H, Kiliç S, et al. Effect of bevacizumab on postoperative adhesion formation in a rat uterine horn adhesion model and the correlation with vascular endothelial growth factor and Ki-67 immunopositivity. Fertil Steril 2011;95:2638-2641.

Pavlidis ET, Ballas KD, Psarras K, et al. Intraperitoneal administration of bevacizumab intraoperatively does not affect abdominal wound healing in rats. Eur Surg Res 2011;47:45-51.
Pamukkale Tıp Dergisi-Cover
  • ISSN: 1309-9833
  • Yayın Aralığı: Yılda 4 Sayı
  • Başlangıç: 2008
  • Yayıncı: Prof.Dr.Eylem Değirmenci
Sayıdaki Diğer Makaleler

Liver-Fatty Acid Binding Proteinin hepatic ensefalopatili hastalarda mortalite öngörme kabiliyeti: Bir prospektif gözlemsel çalışma

ÖZLEM ÖZER ÇAKIR, Aysun TOKER, HÜSEYİN ATASEVEN, Ali DEMİR, Hakkı POLAT, GÖKHAN GÜNGÖR, MURAT BIYIK

Leflunomid methotrexat'a bağlı karaciğer toksisitesini önleyebilir mi?

Nevin ORUÇ, Ufuk KUTLUANA, Ömer ÖZÜTEMİR, Neşe ÇALLI DEMİRKAN, Nadir YÖNETÇİ, Selma DİNÇER TEKEKOĞLU, Mustafa YILMAZ, Beyza AKDAĞ

Aksesuar foramen transversarium

SİBEL ÇIRPAN, Gökşin Nilüfer YONGUÇ, Nüket GÖÇMEN-MAS, METE EDİZER

Gebe sıçanlara bevacizumab uygulayarak preeklampsi çalışmalarında kullanılabilecek deneysel hayvan modeli oluşturulabilir.

Abdullah BOZTOSUN, Şafak ONGAN, Hatice ÖZER, Remzi ATİLGAN, Şehmus PALA

İntertrokanterik femur kırıklarında dinamik kalça çivisi ile proksimal femoral çivisi karşılaştırılması ve maliyet analizi.

Mehmet Veysel BAŞKAN, Ali Çağdaş YÖRÜKOĞLU, Ahmet Nadir AYDEMİR, Nihal BUKER, Nusret ÖK, Ahmet Fahir DEMİRKAN

Erzurum ilinde Kırım Kongo kanamalı ateş sendromuyla izlenen çocuk hastaların geriye dönük olarak değerlendirmesi

SONER SERTAN KARA, Meltem POLAT

Bilgisayarlı tomografi kılavuzluğunda yapılan kesici iğne akciğer biyopsilerindeki komplikasyonlar ve risk faktörleri. Complications and risk factors in computed tomography-guided cutting needle lung biopsies

Furkan Ufuk

Antepartum Hiperekojen Barsak Tanısı Konan Fetusda Postpartum Anal Atrezi Tespiti

Buğra ŞAHİN, Gizem CURA, Fatih ÇELİK, Banuhan ŞAHİN

An Evaluation of the Facet Joint Angle Characteristics on the Development of Lumbar Disc Hernia in Young Patients

Ahmet EROĞLU, İlhan YILMAZ, Metehan ESEOĞLU

Comparison of dynamic hip screw and proximal femoral nail in intertrochanteric femur fractures and cost analysis

Mehmet Veysel BAŞKAN, ALİ ÇAĞDAŞ YÖRÜKOĞLU, AHMET NADİR AYDEMİR, NİHAL BÜKER, NUSRET ÖK, AHMET FAHİR DEMİRKAN